Longevity Startup Doses First Human in Bid to Reverse Age-Related Sight Loss
Isabella WardScienceJun 9, 2026 9:23 AMLongevity Startup Doses First Human in Bid to Reverse Age-Related Sight LossThe FDA recently approved the cellular rejuvenation therapy ER-100 for human clinical trials. ER-100 is the focus of major interest across biotech for its potential to reverse cellular aging. Life Biosciences, based in Boston, says it is developing applications for its technology to tackle a host of age-related diseases in a variety of organs, like fatty liver disease.“Our research has suggested that aging is driven in large part by the loss of epigenetic information, not irreversible damage.
- ▪Isabella WardScienceJun 9, 2026 9:23 AMLongevity Startup Doses First Human in Bid to Reverse Age-Related Sight LossThe FDA recently approved the cellular rejuvenation therapy ER-100 for human clinical trials.
- ▪ER-100 is the focus of major interest across biotech for its potential to reverse cellular aging.
- ▪Life Biosciences, based in Boston, says it is developing applications for its technology to tackle a host of age-related diseases in a variety of organs, like fatty liver disease.“Our research has suggested that aging is driven in large par
WIRED files mainly under tech. We currently carry 478 of its stories.
Opening excerpt (first ~120 words) tap to expand
Isabella WardScienceJun 9, 2026 9:23 AMLongevity Startup Doses First Human in Bid to Reverse Age-Related Sight LossThe FDA recently approved the cellular rejuvenation therapy ER-100 for human clinical trials. While vision is the first target, it could have applications for a variety of age-related disease.Photo-Illustration: WIRED Staff; Getty ImagesCommentLoaderSave StorySave this storyCommentLoaderSave StorySave this storyA longevity startup has dosed its first patient with a drug to reverse age-related sight loss.Life Biosciences is testing its ER-100 drug, which the company claims has restored vision in monkeys, for safety and side effects in a study of around 18 adults over the next year.It will be targeting patients with glaucoma and NAION, two conditions that cause damage to…
Excerpt limited to ~120 words for fair-use compliance. The full article is at WIRED.
Discussion
0 commentsMore from WIRED
